Radiotherapy (RT) after breast-conserving surgery (BCS):
Is a standard treatment option for the management of DCIS
Multifocal disease:
Two or more foci contained within a limited area and usually the same quadrant of the breast:
Is not necessarily a contraindication to BCT
The detrimental effect of multifocality seen in one study:
Was limited to women who did not receive radiotherapy:
Among women treated with breast-conserving surgery plus radiation:
There was no difference in 10-year local recurrence-free survival:
80% v 87%; P = .35
Patients requiring mastectomy for high grade DCIS with comedy necrosis:
May benefit from sentinel node biopsy
In the NSABP-B24 study:
Only patients with hormone receptor positive DCIS benefited from adjuvant tamoxifen
References
1. Rakovitch E, Pignol JP, Hanna W, Narod S, Spayne J, Nofech-Mozes S, et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol. 2007;25(35):5591-5596.
2. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268-1273.